Mithra Announces Positive Results of Ovarian Function Sub-Study which Strengthens Estelle® Contraceptive Efficacy Profile

/in , /by

Effective ovulation inhibition with no single ovulation at cycles 1 and 3 Data further strengthens the contraceptive efficacy profile of Estelle® previously shown in top-line EU/Russia phase III study results Results further support Estelle® as a novel, next-generation combined oral contraceptive for women Liège, Belgium, 6 December 2018 – Mithra (Euronext Brussels: MITRA), a company […]

Read more →

Mithra Reduces Environmental Impact of CDMO facility in Belgium with the Installation of 1800 Solar Panels

/in , /by

Liège, Belgium, 21 November 2018 –  Mithra (Euronext Brussels: MITRA) announces that it has reduced the environmental impact of its CDMO facility in Belgium with the installation of 1800 solar panels. Mithra has also put in place an internal committee within its CDMO with the aim of reducing costs and minimizing the environmental impact of the […]

Read more →

Mithra Signs Exclusive License and Supply Agreement for Vaginal Contraceptive Ring in Australia and New Zealand

/in , /by

Mithra grants exclusive 10-year license for commercialization of vaginal contraception ring in Australia and New Zealand to Neo Health Product to be manufactured at Mithra CDMO facility in Belgium Agreement follows licensing deals for Myring™ with market leaders in the US, Austria, Czech Republic, Chile, Denmark, Russia Liège, Belgium, 20 November 2018 – Mithra (Euronext Brussels: […]

Read more →

Full Estetrol (E4) Program Update Provided at Scientific Advisory Board Meetings

/in , /by

Scientific Advisory Boards consulted for the next stages of development and regulatory approval of Estelle® and Donesta® – Mithra’s late stage contraceptive and menopause candidates Liège, Belgium, 19 November 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces that it held two scientific advisory board (SAB) meetings in New Orleans (LA) at […]

Read more →

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle®

/in , /by

Completion of Estelle® Phase III US/Canada study of Estelle® phase III programme completes Mithra’s most advanced clinical programme EU/Russia study reported positive results achieving primary and secondary endpoints Estelle® Phase III study in US/Canada will report top-line results in Q1 2019 Estelle® : a step closer to become next generation COC on the market Liège, […]

Read more →

New Warrant Plan Approved by Mithra Shareholders

/in /by

Liège, Belgium, 06 November 2018 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that shareholders have approved the issuance of a maximum of 1,881,974 warrants under a new warrant plan (‘Warrant Plan’), for the benefit of key employees, members of the management team and certain directors. The […]

Read more →

Mithra Signs Exclusive License and Supply Agreement with Adcock Ingram for Commercialization of Estelle® in Southern Africa

/in , /by

Mithra is eligible for a downpayment of EUR 1.5 million 20-year exclusive license and supply agreement to generate annual recurring revenues and royalty payments Production at the Mithra CDMO facility Deal forms part of Mithra’s strategy to realise the full potential of the pipeline programs through global partnerships with leaders in Women’s Health Liège, Belgium, […]

Read more →

2018 Update and 2019 Outlook Given at the CPHI Conference

/in , /by

Estelle® Oral Contraception programme on track – US/CANADA Phase III arm due to complete in Q4 2018; partnering discussions ongoing including for us market Preparations for Phase III Donesta® trials moving ahead, including co-partnering discussions Further Marketing authorisations obtained for MyRing™ Liège, Belgium, 10 October 2018 – 20:30 CEST – Mithra (Euronext Brussels: MITRA), a […]

Read more →

Notice of 2018 Extraordinary General Meeting Regarding Proposed Warrant Plan

/in , /by

Liège, Belgium, 5 October 2018 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces its intention to hold an Extraordinary General Meeting (“EGM”) on the 5 November 2018 at 11:00 am in Flémalle, 57 rue de l’Expansion (Belgium). The meeting will consider a new warrant plan whereby a […]

Read more →

Presentation of Donesta® PhIIb Results at the 2018 Annual Meeting of the North American Menopause Society

/in , /by

Liège, Belgium, October 3nd 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces its Phase IIb results for Donesta® will be presented at the 29th Annual Meeting of the North American Menopause Society (NAMS), being held on 3-6 October 2018 in San Diego, CA.  

Read more →